about
Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction.A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia.Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.Evaluation of Different Preparation Procedures of Pathogen Reduction Technology(MirasolĀ®)-Treated Platelets Collected by Plateletpheresis.Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level.The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice.Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light.Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation.Chemical and biological mechanisms of pathogen reduction technologiesThe effect of riboflavin and ultraviolet light on the infectivity of arboviruses.Selective inactivation of viruses in the presence of human platelets: UV sensitization with psoralen derivatives.Treatment of Whole Blood With Riboflavin and UV Light: Impact on Malaria Parasite Viability and Whole Blood StoragePhotochemical eradication of methicillin-resistant Staphylococcus aureus by blue light activation of riboflavin.The utility of pathogen inactivation technology: a real-life example of Leishmania infantum inactivation in platelets from a donor with an asymptomatic infectionTreatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination.Reduction of prion infectivity in packed red blood cells.Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.Riboflavin and ultraviolet light: impact on dengue virus infectivity.Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells.Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial.Pathogen reduction of whole blood: utility and feasibility.Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro.Efficiency of riboflavin and ultraviolet light treatment against high levels of biofilm-derived Staphylococcus epidermidis in buffy coat platelet concentrates.Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage.Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment.Characterization of posttransfusion Plasmodium falciparum infection in semi-immune nonparasitemic patients.Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model.The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment.Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light.Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment--a comparative study.In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system.Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns.Refrigerated storage of lyophilized and rehydrated, lyophilized human red cells.Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons.
P50
Q33367647-7444B41E-E12A-4FED-8733-4A285FD5C945Q33405052-824A5705-9552-4B8B-8444-6FBBF9DE1076Q33495369-3231A79D-2A73-44B0-8FFA-BC3BB3ACD206Q33852543-7BD1B40E-642B-4DFD-8B25-56B770757367Q34263548-3E6D8771-68DD-49F7-8167-83C030FAAE4BQ34344603-6D3B31C6-12CB-46CA-82B2-D4D44CA00585Q34560849-1F6DC673-A60D-47A8-B67B-45F1F18E8BDDQ34565186-C3AD2C3D-C04E-4387-9CE7-A66308825C58Q34704337-0D35EA67-3F87-421E-9C3D-A2FBF1088C23Q34763224-B728A7C8-0C1B-4DFF-B448-1882748E6A14Q34777948-87BABFC9-93C0-420D-848B-34E7BC10E806Q35394095-00148C56-6E72-4DDF-9EA7-59081953623EQ35487840-D89F4C5F-ED85-45F4-B885-2D96244CB040Q35841288-AE277449-C9E2-4B14-88EB-B9FFE4A63E2CQ36282177-AA5B7705-1307-4068-9A4C-35A73068DDB6Q36393465-A114D33C-7DE2-4448-A2B1-A610CC69227FQ36408117-A28A5309-751B-4AB1-A99D-2FB204DD1A84Q37022481-8129E816-3065-453E-8791-73981ED75DECQ37903671-1A5B90F1-C6AF-4A86-9D4E-6BCA5F033578Q38794017-4D2EB05D-61B5-48BE-AEA5-5D1AAEA09F6FQ38808618-3EB6EDC6-2D43-40C5-B7CB-D50165D4D707Q38934537-32D8F759-114A-47E2-B6B0-CA7BDF414115Q39820533-A65E56A8-C954-48DD-AA19-304046294E09Q40056466-7DC22A9D-8EBA-4644-9BED-D6208747712DQ40113068-E9BF8318-FB75-4DE9-A390-D6B9F999FE48Q40264266-DAC74DE8-8FF7-495A-B77E-85D8B4DC98DFQ40267288-98BA6F03-19DB-4516-B951-3A9E0C1941ACQ40384711-5771368E-FCD2-4B56-A749-91D9D7AE6031Q40638270-140D2C97-7B41-4EBF-9550-17F2839602B9Q41591514-558E2BB9-2992-4D48-A5B3-6B96E70E0B9FQ41897296-95D92B0F-5E99-4D07-A442-37DCA62034AFQ42269799-869F75D2-3DB2-434B-8A45-F8C99AE92151Q42278717-E17C1D2B-D0D0-42D1-8BC0-8EDED1F8A88AQ42286547-B7E0E2EF-7A0E-4FC7-B79F-878043D61BD6Q43067643-48D2D72A-3B3C-480A-934B-4421B127390BQ44164159-6E1E667D-699A-4C4B-BA4C-4423E12F513FQ45050105-840BCADC-C2E7-4FA8-A9E6-FDC1F544922CQ46075116-E9C47DC5-4F40-4C93-A44F-0FC0AFE71809Q46217304-F360477A-69BF-437E-834E-5DE7FD61BF8FQ46292960-8119518B-7657-46B6-B7F9-D05F6EFAF966
P50
description
researcher
@en
wetenschapper
@nl
Õ°Õ„ÕæÕ”Õ¦ÕøÕæÕøÕ²
@hy
name
Raymond P Goodrich
@ast
Raymond P Goodrich
@en
Raymond P Goodrich
@es
Raymond P Goodrich
@nl
type
label
Raymond P Goodrich
@ast
Raymond P Goodrich
@en
Raymond P Goodrich
@es
Raymond P Goodrich
@nl
prefLabel
Raymond P Goodrich
@ast
Raymond P Goodrich
@en
Raymond P Goodrich
@es
Raymond P Goodrich
@nl
P106
P1153
7102721099
P31
P496
0000-0002-5945-4571